Extensive Stage Small Cell Lung Cancer Combination Treatment

 

Trial Objective

Extensive stage small cell lung cancer (ES-SCLC) is an aggressive type of cancer that can rapidly spread to other areas of the body. This type of cancer currently has limited treatment options. The purpose of this study is to determine the efficacy and safety of lurbinectedin (a type of chemotherapy) when combined with atezolizumab (an immunotherapy treatment) as a maintenance treatment for those with ES-SCLC. This combination treatment will be compared a treatment of atezolizumab alone. Participants will be randomly chosen to receive a combination of lurbinectedin and atezolizumab or atezolizumab alone. They will not know which treatment they are receiving. The treatments are delivered by IV infusion. Participants also may be asked to provide blood samples and have a physical exam.

Enrollment

Active Clinical Trials Currently Recruiting

Who Can Participate

Individuals who are being treated at National Jewish Health with confirmed extensive-stage small-cell lung cancer (ES-SCLC) who have not yet started treatment.

Age: 18+    Gender: Any Gender


Estimated Time Commitment

Two or more years



Payment & Reimbursement  

Payment: Provided

Travel Reimbursement: Available

Trial Contact

For more information, contact:

Jami Henriksen
303.398.1233

Request More Information

Trial Location

National Jewish Main Campus, Denver, CO

Trial Sponsors

Hoffmann-La Roche

Principal Investigators


Request More Information

By completing this form, you agree to learn more about this study and see if you qualify.


*
*
*
*
 I would also like to receive periodic emails with health information, news and clinical research updates from National Jewish Health: